BIVI

BIOVIE INC. (BIVI) - 10-Q Summary

Business Context and Reporting Period

Company: BioVie Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: BioVie is a clinical-stage biopharmaceutical company developing therapies for neurological/neuro-degenerative disorders (Alzheimer's, Parkinson's, Long COVID) and liver disease. The company has no product revenue and relies on capital raises and grants to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by $5.3 million for the three months ended March 31, 2025, compared to the same period in 2024. This was driven by a $4.4 million decrease in R&D expenses and a $388,000 decrease in SG&A expenses.
• R&D Expenses: R&D expenses dropped significantly from $5.7 million (Q3 2024) to $1.3 million (Q3 2025). This reflects the completion of prior clinical trials (specifically the Alzheimer's Phase 3) and a reduction in clinical team payroll and consultant usage.
• Debt Elimination: The company paid off its $15 million loan from Avenue Venture Opportunities in full on December 1, 2024, including a $850,000 loan premium. Consequently, interest expense dropped from $629,000 in Q3 2024 to $5,000 in Q3 2025.
• Capital Raises: During the nine months ended March 31, 2025, the company raised approximately $15.7 million in net proceeds from common stock issuances and $2.9 million from warrant exercises.
• Grant Reimbursements: The company received reimbursements of approximately $2.5 million (Q3) and $2.8 million (9-month) from the U.S. Department of Defense for the Long COVID clinical trial, which were recorded as credits against R&D expenses.

Guidance, Outlook, Risks, and Unusual Items

• Clinical Pipeline Updates:
  • Parkinson's Disease: A new Phase 2 study of bezisterim for new-onset PD commenced in April 2025.
  • Long COVID: The company anticipates commencing a trial for neurological symptoms associated with Long COVID in May 2025, funded by a $13.1 million DOD grant.
  • Liver Disease: Finalizing Phase 3 protocol for BIV201 (terlipressin) targeting a broader ascites patient population.
• Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern without additional financing, as it has no revenue and an accumulated deficit of $348.7 million.
• Legal Proceedings:
  • Securities Class Action: A consolidated class action lawsuit regarding the Phase 3 Alzheimer's trial data was denied a motion to dismiss on March 27, 2025, and has moved to fact discovery.
  • Derivative Suits: Two shareholder derivative lawsuits were filed in late 2024 and early 2025 alleging breach of fiduciary duties related to the class action claims.
• Nasdaq Compliance Risk: The company faces a risk of delisting if it fails to meet the $1.00 minimum bid price requirement by August 6, 2025 (one year after the previous reverse split), as it would not be eligible for a compliance period under new SEC rules.
• Unusual Items: The company recorded "deemed dividends" totaling $369,465 for the nine months ended March 31, 2025, related to ratchet adjustments on warrants issued to Acuitas Group Holdings.

Investor Verification Checklist

• Cash Runway: Verify the current cash burn rate against the $23.2 million cash balance to determine the runway before the next capital raise is required.
• Legal Exposure: Monitor the progress of the securities class action and derivative lawsuits, as fact discovery has commenced and could result in significant costs or settlements.
• Nasdaq Status: Track the stock price relative to the $1.00 minimum bid price requirement ahead of the August 6, 2025 deadline to assess delisting risk.
• Clinical Milestones: Confirm the start dates and enrollment progress for the new Parkinson's (Sunrise) and Long COVID trials.
• Dilution: Review the impact of outstanding warrants (9.6 million shares) and options (887k shares) on future equity dilution.